



17 May 2024

Our Ref: RFI 57474

**Freedom of Information Act 2000
Information in Relation to Cancer Treatment**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 27 March 2024. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Surgery & Elective, Maternity & Paediatric Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Officer

Please provide the data on numbers of patients from the electronic prescribing system.

Breast Cancer

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines, listed within Table 1, in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

A1. Please see Table 1 for the number of patients treated, within the latest 3 months, for the listed medication.

Table 1

Medication	No. of Patients Treated
Abemaciclib (Verzenios)	13
Alpelisib (Piqray)	Nil
Fulvestrant (fulvestrant or Faslodex)	14
Palbociclib (Ibrance)	44
Ribociclib (Kisqali)	18

Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

A2. There have been 11 patients treated with abemaciclib (Verzenios) for early breast cancer, within the latest 3 months.

Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent, within Table 2, in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

A3. Please see Table 2 for patients who received abemaciclib (verzenios) with the listed treatments, within the latest 3 months.

Table 2

Treatment	No. of Patients Treated
Curative	11
Palliative	2
Not known / stated	Nil

Q4. How many patients were treated with the following medicines, in Table 3, in combination with fulvestrant in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

A4. Please see Table 3 for the number of patients treated with the listed medication in combination with fulvestrant in the latest 3 months.

Table 3

Medication	No. of Patients Treated
Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	Nil
Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	9
Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	Nil

Prostate Cancer

Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines, within Table 4, in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

A5. Please see Table 4 for the number of patients treated with the listed medication within the latest 3 months.

Table 4

Medication	No. of Patients Treated
Abiraterone (Zytiga or generic abiraterone)	24
Apalutamide (Erleada)	3
Cabazitaxel (Jevtana or generic cabazitaxel)	2
Darolutamide (Nubeqa)	5
Enzalutamide (Xtandi)	79

Q6. How many patients were treated with docetaxel specifically for prostate cancer (ICD-10 code = C61) in the 3 months between the start of October 2023 and end of December 2023? Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

A6. There were 6 patients treated with docetaxel specifically for prostate cancer within the latest 3 months.

Q7. How many patients were treated with the following medicine, within table 5, combinations in the 3 months between the start of October 2023 and end of December 2023? Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

A7. Please see Table 5 for the number of patients treated with the listed medication combinations within the latest 3 months.

Table 5

Medication	No. of Patients Treated
Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy	24
Apalutamide (Erleada) + Androgen Deprivation Therapy	3
Darolutamide (Nubeqa) + Docetaxel + ADT	Nil
Enzalutamide (Zytiga) + Androgen Deprivation Therapy	73

Ovarian and Endometrial Cancers

Q8. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023? Please provide data for the latest 3-month period, if Oct to Dec 23 is not available.

- **Dostarlimab (Jemperli)**
- **Niraparib (Zejula)**
- **Rucaparib (Rubraca)**

A8. There were no patients treated with the listed medication within the latest 3 months.

Q9. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

- **Olaparib in total**
- **Olaparib monotherapy**
- **Olaparib + bevacizumab in combination**
- **Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin**

A9. There were no patients who were treated for ovarian, fallopian or primary peritoneal cancers with the listed medication as monotherapy or in combination within the lasts 3 months.

Q10. How many patients were treated for endometrial cancer with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

- ***Dostarlimab monotherapy***
- ***Dostarlimab + platinum-based chemotherapy, or dostarlimab + carboplatin and paclitaxel***
- ***Pembrolizumab (Keytruda) in total***
- ***Lenvatinib (Lenvima) in total***
- ***Pembrolizumab monotherapy***
- ***Pembrolizumab + Lenvatinib (Lenvima) in combination***

A10. There were no patients treated for endometrial cancer with the listed medications as monotherapy or in combination within the latest 3 months.

Q11. Please provide data on usage of medicines from the hospital pharmacy system for medications listed within table 6 for the time period Jan 2019 to Feb 2024.

Data to include:

- ***Calendar Year***
- ***Calendar Month***
- ***Name of Health Board/Trust***
- ***Drug Substance (INN name of drug)***
- ***Drug Product Pack Name***
- ***Quantity Unit of Measure (UOM)***
- ***Quantity Issued***

A11. Please note the Trust can only provide figures up to November 2023 due to migrating to the new encompass system. The data validation for this system is currently ongoing.

Please see Table 6 for data on the usage of the listed medications from January 2019 to November 2023.

Please be advised that the data provided are totals for the requested time period.

The Trust is unable to provide the requested data, broken down by month and year, as the information is not held on a central information system. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this statement acts as a Refusal Notice in regards to part of question 11, the breakdown of the requested data.

Table 6

South Eastern Health & Social Care Trust			
Drug Name	Drug Pack Name	Quantity Unit of Measure	Quantity Issued
Abemaciclib	Abemaciclib 100mg tablets	Tablets	784
Abemaciclib	Abemaciclib 150mg tablets	Tablets	1624
Abemaciclib	Abemaciclib 75mg tablets	Tablets	392
Alpelisib	N/A	N/A	Nil
Palbociclib	Palbociclib 125mg tablets	Tablets	10,311
Palbociclib	Palbociclib 100mg tablets	Tablets	8925
Palbociclib	Palbociclib 75mg tablets	Tablets	8022
Ribociclib	Ribociclib 200mg tablets	Tablets	10,500
Abiraterone	Abiraterone 500mg tablets	Tablets	130,480
Apalutamide	Apalutamide 60mg tablets	Tablets	9408
Darolutamide	Darolutamide 300mg tablets	Tablets	4032
Enzalutamide	Enzalutamide 40mg tablets	Tablets	477,120
Dostarlimab	N/A	N/A	Nil
Niraparib	N/A	N/A	Nil
Olaparib	N/A	N/A	Nil
Rucaparib	N/A	N/A	Nil